Zhejiang Hisoar Pharmaceutical Co., Ltd.
海翔药业
002099
Shenzhen Stock Exchange
Company Profile
Company adopted the operation model “Driving by the "two engines" of Pharmaceutical and dyestuff”: pharmaceutical facility was established complying with internal quality management system and EHS management system requirements, passed the GMP inspection from US and EU authorities since 2005, become the only strategic partner with Germany BI in China since 2008, and the facility of formulation passed the EU inspection in 2016 becoming one of few domestic formulation companies which can export the products to EU; dyestuff business is an industry chain from chemical material to dyestuff commercialization. Company drafts 5 national and 9 industry product specifications as well as the reactive blue KN-R “Made in Zhejiang” specification. The main product of dyestuff is reactive blue series, in which KN-R’s production and marketing always at the top of world, with 60% global market share, product with the advantage of salt tolerating, large solubility, which is suitable for different cloth printing and dyeing process requirements, moreover saving water quantity use and dye take up, quality stable and excellent, those comes to the good and extensive reputation from the international.
Full description
Zhejiang Hisoar Pharmaceutical Co., Ltd is a comprehensive pharmaceutical company, focused on business of featured API, formulation, fine chemical, dyestuff and dyestuff intermediate. Company was listed on Shenzhen stock exchange in 2006, with registered assets of RMB 1.621billion and total assets of RMB 7.593billion, having its subsidiaries in Zhejiang, Jiangsu, Shanghai, Germany, Hong Kong and Singapore including total employees more than 2600.Hisoar ranks among the top 100 innovative pharmaceutical companies in China, honored as key high-tech enterprise of National Torch Program, good faith demonstration enterprise of Zhejiang Province, outstanding self-export enterprise of Zhejiang Province. Company has national post-doctor research work station, provincial level academician expert work station, provincial level enterprise technology center and provincial level enterprise research institute and so on.There are dozens of pharmaceutical products registered with US FDA and CEP (COS) granted, and facility passed the GMP inspections from US FDA, EU, Japan and China authorities etc.. The capacity of Clindamycin products is always at the top of word and Penam products is also at the top of country. Hisoar is to keep the long term cooperation with international pharmaceutical companies such as Pfizer, BI, BASF, Sanofi, Norvatis etc., especially the strategic partner with BI. The exporting of dyestuff to EU, US and Asia is active in more than 30 countries. Especially, the market share of the product reactive blue KN-R taking up to 60% of the world. Our dyestuff business is leading of industry no matter on the aspects of industry scale, technology quality, and product application etc. Reactive blue KN-R has been awarded as Chinese brand product and national outstanding Torch Program, as one of three Chinese great brand dyestuffs. Hisoar is committed to be based on China, having layout all over the world, promoting high level cooperation and Sino-foreign interaction, developed as a top pharmaceutical company with comprehensive industrial chain operation and competitive industrial value chain integrating with chemical API (includes fine intermediates),bio-pharmaceuticals and pharmaceutical formulation; to maintain the reactive blue KN-R world leading position, develop the new projects of high environmental protected and disperse dyestuffs and properly introduce other dyestuffs on basis of three-primary colors(Red, Yellow and Blue) in order to expand the product portfolio for the final purpose to be a world class dyestuffs supplier with variety products.